Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling

John T. Vetto; Eddy C. Hsueh; Brian R. Gastman; Larry D. Dillon; Federico A. Monzon; Robert W. Cook; Jennifer Keller; Xin Huang; Andrew Fleming; Preston Hewgley; Pedram Gerami; Sancy Leachman; Jeffrey D. Wayne; Adam C. Berger; Martin D. Fleming

doi:10.2217/fon-2018-0912

Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling

John T. Vetto, Eddy C. Hsueh, Brian R. Gastman, Larry D. Dillon, Federico A. Monzon, Robert W. Cook, Jennifer Keller, Xin Huang, Andrew Fleming, Preston Hewgley, Pedram Gerami, Sancy Leachman, Jeffrey D. Wayne, Adam C. Berger, Martin D. Fleming

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.

Original language	English (US)
Pages (from-to)	1207-1217
Number of pages	11
Journal	Future Oncology
Volume	15
Issue number	11
DOIs	https://doi.org/10.2217/fon-2018-0912
State	Published - Apr 2019

Keywords

biomarker
gene expression profiling
melanoma
prognosis
sentinel lymph node biopsy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2018-0912

Cite this

Vetto, J. T., Hsueh, E. C., Gastman, B. R., Dillon, L. D., Monzon, F. A., Cook, R. W., Keller, J., Huang, X., Fleming, A., Hewgley, P., Gerami, P., Leachman, S., Wayne, J. D., Berger, A. C., & Fleming, M. D. (2019). Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling. Future Oncology, 15(11), 1207-1217. https://doi.org/10.2217/fon-2018-0912

Vetto, JT, Hsueh, EC, Gastman, BR, Dillon, LD, Monzon, FA, Cook, RW, Keller, J, Huang, X, Fleming, A, Hewgley, P, Gerami, P, Leachman, S, Wayne, JD, Berger, AC & Fleming, MD 2019, 'Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling', Future Oncology, vol. 15, no. 11, pp. 1207-1217. https://doi.org/10.2217/fon-2018-0912

@article{450db5173248422cbaa6dfa156d9b2e7,

title = "Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling",

abstract = "Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.",

keywords = "biomarker, gene expression profiling, melanoma, prognosis, sentinel lymph node biopsy",

author = "Vetto, {John T.} and Hsueh, {Eddy C.} and Gastman, {Brian R.} and Dillon, {Larry D.} and Monzon, {Federico A.} and Cook, {Robert W.} and Jennifer Keller and Xin Huang and Andrew Fleming and Preston Hewgley and Pedram Gerami and Sancy Leachman and Wayne, {Jeffrey D.} and Berger, {Adam C.} and Fleming, {Martin D.}",

note = "Publisher Copyright: {\textcopyright} 2019 Castle Biosciences, Inc.",

year = "2019",

month = apr,

doi = "10.2217/fon-2018-0912",

language = "English (US)",

volume = "15",

pages = "1207--1217",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "11",

}

TY - JOUR

T1 - Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling

AU - Vetto, John T.

AU - Hsueh, Eddy C.

AU - Gastman, Brian R.

AU - Dillon, Larry D.

AU - Monzon, Federico A.

AU - Cook, Robert W.

AU - Keller, Jennifer

AU - Huang, Xin

AU - Fleming, Andrew

AU - Hewgley, Preston

AU - Gerami, Pedram

AU - Leachman, Sancy

AU - Wayne, Jeffrey D.

AU - Berger, Adam C.

AU - Fleming, Martin D.

PY - 2019/4

Y1 - 2019/4

N2 - Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.

AB - Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and 1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival was 99.3% for patients ≥55 years with class 1A, T1-T2 tumors and 55.0% for class 2B, SLN-positive, T1-T2 tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy.

KW - biomarker

KW - gene expression profiling

KW - melanoma

KW - prognosis

KW - sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85064409004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064409004&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0912

DO - 10.2217/fon-2018-0912

M3 - Article

C2 - 30691297

AN - SCOPUS:85064409004

SN - 1479-6694

VL - 15

SP - 1207

EP - 1217

JO - Future Oncology

JF - Future Oncology

IS - 11

ER -

Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this